229 related articles for article (PubMed ID: 30260993)
1. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
Margulis AV; Linder M; Arana A; Pottegård A; Berglind IA; Bui CL; Kristiansen NS; Bahmanyar S; McQuay LJ; Atsma WJ; Appenteng K; D'Silva M; Perez-Gutthann S; Hallas J
PLoS One; 2018; 13(9):e0204456. PubMed ID: 30260993
[TBL] [Abstract][Full Text] [Related]
2. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
3. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S
Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study.
Hallas J; Margulis AV; Pottegård A; Kristiansen NS; Atsma WJ; Appenteng K; de Vogel S; Kaye JA; Perez-Gutthann S; Arana A
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):612-619. PubMed ID: 29345103
[TBL] [Abstract][Full Text] [Related]
7. A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
Milsom I; Schiotz HA; Svensson M; Kilany S; Hansson F
Scand J Urol; 2019 Aug; 53(4):246-254. PubMed ID: 31195868
[No Abstract] [Full Text] [Related]
8. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
10. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.
Margulis AV; Hallas J; Pottegård A; Kristiansen NS; Atsma WJ; Franks B; D'Silva M; Varas-Lorenzo C; Perez-Gutthann S; Arana A
Eur J Clin Pharmacol; 2018 Feb; 74(2):193-199. PubMed ID: 29134254
[TBL] [Abstract][Full Text] [Related]
12. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
Armstrong EP; Malone DC; Bui CN
J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
[TBL] [Abstract][Full Text] [Related]
14. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
16. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
17. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
Ko Y; Malone DC; Armstrong EP
Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
[TBL] [Abstract][Full Text] [Related]
19. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
[TBL] [Abstract][Full Text] [Related]
20. Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.
Kaye JA; Margulis AV; Fortuny J; McQuay LJ; Plana E; Bartsch JL; Bui CL; Perez-Gutthann S; Arana A
Pharmacotherapy; 2017 Jun; 37(6):673-683. PubMed ID: 28370075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]